Clinical Trial: Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 ? 50%
Study Status: Completed
Recruit Status: RECRUITING
Condition: Advanced Non-Small Cell Lung Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (
Brief Summary:
The study is researching an investigational drug, called BNT116, in combination with cemiplimab.BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs" in this form.The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).The aims of the study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating…
Read more